RxDoctor Payments DataLook up a doctor →

Arvindh Kanagasundram, MD

Cardiovascular Disease · Nashville, TNNPI 1932381795

Payments from drug & device makers

$912,433in general payments, 2019–2025

Across 332 payments — averaging $2748.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$683K
  • Abbott$103K
  • Medtronic$68K
  • Johnson & Johnson$34K
  • Medical Device Business Services, Inc.$11K
  • Biosense Webster, Inc.$9K
  • plus $4K from 5 others

What the payments were for

  • Consulting fees$67,75042%
  • Speaking & faculty fees$39,82025%
  • Travel & lodging$49,04230%
  • Food & beverage$4,7623%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$912,433 in reported general payments places this provider in the 95th percentile of 429 cardiovascular disease providers in Tennessee.

See all cardiovascular disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$335,325
Medicare patients
1,909
Services billed
4,135

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban435$504,597
XareltoRivaroxaban120$160,316
Dofetilide75$11,977
Flecainide Acetate186$8,092
Mexiletine Hcl60$7,893
SotalolSotalol Hcl104$3,015
Metoprolol Succinate154$2,820
Propafenone Hcl60$2,549
Amiodarone Hcl105$1,627
Metoprolol Tartrate115$1,336
Disopyramide Phosphate12$1,218
Digoxin26$583
Verapamil ErVerapamil Hcl11$434
Diltiazem 24hr Er (Cd)Diltiazem Hcl15$281
Warfarin Sodium28$253

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$129$504,597435 claims
Johnson & JohnsonXarelto$33,749$160,316120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 429 cardiovascular disease providers in Tennessee.

Other cardiovascular disease in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →